These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 17593237

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 4. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 5. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 6. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
    Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S.
    Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 12. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C, Shimizu T, Arakawa M, Mita T, Fujitani Y, Watada H, Kawamori R, Hirose T.
    Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
    [Abstract] [Full Text] [Related]

  • 13. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [Abstract] [Full Text] [Related]

  • 14. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
    Boehm BO, Vaz JA, Brøndsted L, Home PD.
    Eur J Intern Med; 2004 Dec; 15(8):496-502. PubMed ID: 15668084
    [Abstract] [Full Text] [Related]

  • 15. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
    Yang W, Gao Y, Liu G, Chen L, Fu Z, Zou D, Feng P, Zhao Z.
    Curr Med Res Opin; 2010 Jan; 26(1):101-7. PubMed ID: 19916705
    [Abstract] [Full Text] [Related]

  • 16. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 17. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.
    Parkner T, Møller MK, Chen JW, Laursen T, Jørgensen C, Smedegaard JS, Lauritzen T, Christiansen JS.
    Diabetes Obes Metab; 2008 Jul; 10(7):556-63. PubMed ID: 17593233
    [Abstract] [Full Text] [Related]

  • 18. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 19. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L, Mannucci E, Dicembrini I, Rotella CM.
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [Abstract] [Full Text] [Related]

  • 20. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.